Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

VBI Vaccines Inc

Initiate Phase 1 clinical studies of VBI-2905, the eVLP-based COVID-19 vaccine candidate

Delivered after the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
10 Mar 2021
Due
30 Jun 2021
Delivered
September 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“VBI and CEPI expect to initiate Phase 1 studies of VBI-2905 – the first eVLP-based vaccine candidate in the CEPI portfolio - mid-year 2021.”

What we found

Evidence strength A What the grades mean

The Phase Ib portion assessing VBI-2905 was initiated in September 2021, after the mid-2021 deadline; the August 2021 filing had guided to Q3 2021.

  • A
    VBI Vaccines Inc 10-Q filed 2021-08-02 Regulatory filing · published 2 Aug 2021 · retrieved 27 Oct 2026 · kept permanently by the SEC
    “the next phase of the ongoing adaptive Phase I/II study is expected to initiate in Q3 2021 and will assess VBI-2905” ✓ confirmed on the page
  • A
    VBI Vaccines Inc 10-Q filed 2021-11-08 Regulatory filing · published 8 Nov 2021 · retrieved 27 Oct 2026 · kept permanently by the SEC
    “the Phase Ib portion of the ongoing Phase I study was initiated in September 2021 designed to assess VBI-2905, our eVLP vaccine candidate directed against the SARS-CoV-2 Beta variant” ✓ confirmed on the page
  • A
    VBI Vaccines Inc 10-K filed 2022-03-07 Regulatory filing · published 7 Mar 2022 · retrieved 27 Oct 2026 · kept permanently by the SEC
    “the Phase Ib portion of the ongoing Phase I study was initiated in September 2021 and was designed to assess VBI-2905” ✓ confirmed on the page

Checked 27 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical milestone
Indicative materiality
Medium rules
Action
Initiate
Deliverable
Phase 1 study of VBI-2905 vaccine candidate
Language
Expected (“expects”, “plans”)
In the company’s control
Medium
Specificity
Medium
Depends on
Partner

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you VBI Vaccines Inc? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C764195-025556 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.